Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis - 10/01/08
pages | 3 |
Iconographies | 0 |
Vidéos | 0 |
Autres | 0 |
Abstract |
Objectives |
Analyse the effects of anti-tumor necrosis factor therapy on serum levels of lipid in patients with rheumatoid arthritis (RA).
Methods |
Twenty-nine patients (26 females, 3 males) with established RA undergoing anti-TNF therapy (n=12, adalimumab; n=11, infliximab; n=6, etanercept) were recruited. Total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides (TG), and apolipoproteins (apo b and apo a) were assessed at baseline and after 14 weeks of treatment.
Results |
The disease activity index score (DAS28) was 5.19±0.90 and decreased to 3.46±0.97 at 16 weeks (p<0.001). There was no change neither in the levels of TC (5.65±0.98mmol/l vs 5.78±1.06mmol/l; p=0.43), TG (1.40±0.79mmol/l vs 1.45±0.67mmol/l; p=0.59), HDL-C (1.92±0.49mmol/l vs 1.97±0.49mmol/l; p=0.36), apo a1 (1.92±0.28g/l vs 1.99±0.29g/l; p=0.06), and LDL-C (3.41±0.91mmol/l vs 3.47±0.96mmol/l; p=0.66), nor in apo b (1.126±0.302g/l vs 1.13±0.28g/l; p=0.89), atherogenic index (3.13±1.05 vs 3.09±0.89; p=0.69) or the apo b/apo a1 ratio (0.58±0.25 vs 0.56±0.22; p=0.33).
Conclusion |
The favourable effect of anti-tumor necrosis factor therapy on cardiovascular morbidity is not related to effects on lipid metabolism.
Le texte complet de cet article est disponible en PDF.Keywords : Lipids, Anti-TNF-α, Rheumatoid arthritis, Atheroma
Plan
Vol 75 - N° 1
P. 22-24 - janvier 2008 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?